ABSTRACT
Background ‘Coronavirus disease 2019 (COVID-19) is a rapidly changing disease. So, in this study, we evaluated the evolution of COVID-19 presentation and course in hemodialysis patients (HD).
Methods We retrospectively compared clinical data and outcomes of HD patients affected by COVID-19 during the first pandemic waves of 2020 (from March to December 2020-Group 1) with patients diagnosed with COVID-19 from September 2021 to February 2022 (Group 2), after the full completion of vaccination. Then, we distinguished among them patients responsive (antibody levels > 13 binding antibody units/ml) and unresponsive to the vaccine. We collected data on COVID-19 clinical presentation, laboratory examinations, and outcomes.
Results Group 1 was constituted of 44 patients (69.3±14.6 years) and Group 2 of 55 patients (67.4±15.3 years). Among Group 2, fifty-two patients (95%) were vaccinated, 43 of them (83%) with three doses. Patients of Group 2, compared with Group 1, were more often asymptomatic (38 vs 10%, p=0.002), and reported less frequent fever and pulmonary involvement. At diagnosis, the Group 2 showed a significantly higher number of lymphocytes (0.97±0.45 vs 0.69±0.35 cells x109/L, p=0.008) and lower levels of circulating IL-6 (16±13.3 vs 41±39.4 pg/ml, p=0.002). Moreover, in Group 2, inflammatory parameters significantly improved after a few days from diagnosis. Patients of Group 2 presented a lower hospitalization rate (12.7 vs 38%, p=0.004), illness duration (18.8±7.7 vs 29.2±19.5 days, p=0.005), and mortality rate (5.4 vs 25%, p= 0.008). Finally, responders to the vaccination (80% of the vaccinated patients) compared with non-responders showed a reduction in infection duration and hospitalization (5 vs 40%, p=0.018).
Conclusions COVID-19 presentation and course in HD patients have improved over time after the implementation of vaccine campaigns. However, due to the evolving nature of the disease, active surveillance is necessary.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was performed according to the Declaration of Helsinki and was approved by the local Ethics Committee (N. Registro CER Liguria: 135/2020). All participants provided written informed consent before enrollment.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
